Tevogen Bio Holdings announced the completion of its business combination with Semper Paratus Acquisition. The combined company’s common stock and warrants begin trading today on the Nasdaq under the ticker symbols TVGN and TVGNW.
Tevogen is a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.
Immediately after giving effect to the business combination, there were 165,421,084 shares of common stock outstanding.
Semper Paratus shareholders approved the deal two weeks ago. Total redemptions reached about 99.8% of the original outstanding shares. Tevogen had secured multiple convertible notes from outside investors.
When announced in June, the deal had a pro forma equity value of approximately $1.2 billion.
Sempter Paratus raised $345 million in a November 2021 IPO. The SPAC in May of last year sold its sponsor equity to SSVK Associates. Read more.
